1
|
Lozano-Soldevilla D. On the Physiological Modulation and Potential Mechanisms Underlying Parieto-Occipital Alpha Oscillations. Front Comput Neurosci 2018; 12:23. [PMID: 29670518 PMCID: PMC5893851 DOI: 10.3389/fncom.2018.00023] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2017] [Accepted: 03/20/2018] [Indexed: 12/25/2022] Open
Abstract
The parieto-occipital alpha (8–13 Hz) rhythm is by far the strongest spectral fingerprint in the human brain. Almost 90 years later, its physiological origin is still far from clear. In this Research Topic I review human pharmacological studies using electroencephalography (EEG) and magnetoencephalography (MEG) that investigated the physiological mechanisms behind posterior alpha. Based on results from classical and recent experimental studies, I find a wide spectrum of drugs that modulate parieto-occipital alpha power. Alpha frequency is rarely affected, but this might be due to the range of drug dosages employed. Animal and human pharmacological findings suggest that both GABA enhancers and NMDA blockers systematically decrease posterior alpha power. Surprisingly, most of the theoretical frameworks do not seem to embrace these empirical findings and the debate on the functional role of alpha oscillations has been polarized between the inhibition vs. active poles hypotheses. Here, I speculate that the functional role of alpha might depend on physiological excitation as much as on physiological inhibition. This is supported by animal and human pharmacological work showing that GABAergic, glutamatergic, cholinergic, and serotonergic receptors in the thalamus and the cortex play a key role in the regulation of alpha power and frequency. This myriad of physiological modulations fit with the view that the alpha rhythm is a complex rhythm with multiple sources supported by both thalamo-cortical and cortico-cortical loops. Finally, I briefly discuss how future research combining experimental measurements derived from theoretical predictions based of biophysically realistic computational models will be crucial to the reconciliation of these disparate findings.
Collapse
|
2
|
Baijot S, Deconinck N, Slama H, Massat I, Colin C. Behavioral and neurophysiological study of attentional and inhibitory processes in ADHD-combined and control children. Acta Neurol Belg 2013; 113:477-85. [PMID: 23797351 DOI: 10.1007/s13760-013-0219-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2012] [Accepted: 06/10/2013] [Indexed: 10/26/2022]
Abstract
This study compares behavioral and electrophysiological (P300) responses recorded in a cued continuous performance task (CPT-AX) performed by children with attention deficit hyperactivity disorder-combined subtype (ADHD-com) and age-matched healthy controls. P300 cognitive-evoked potentials and behavioral data were recorded in eight children with ADHD (without comorbidity) and nine control children aged 8-12 years while performing a CPT-AX task. Such task enables to examine several kinds of false alarms and three different kinds of P300 responses: the "Cue P300", the "Go P300" and the "NoGo P300", respectively, associated with preparatory processing/attentional orienting, motor/response execution and motor/response inhibition. Whereas hit rates were about 95% in each group, ADHD children made significantly more false alarm responses (inattention- and inhibition-related) than control children. ADHD children had a marginally smaller Cue P300 than the control children. Behavioral and electrophysiological findings both highlighted inhibition and attention deficits in ADHD-com children in the CPT-AX task. A rarely studied kind of false alarm, the "Other" FA, seems to be a sensitive FA to take into account, even if its interpretation remains unclear.
Collapse
|
3
|
Sarris J, Laporte E, Scholey A, King R, Pipingas A, Schweitzer I, Stough C. Does a medicinal dose of kava impair driving? A randomized, placebo-controlled, double-blind study. TRAFFIC INJURY PREVENTION 2013; 14:13-17. [PMID: 23259514 DOI: 10.1080/15389588.2012.682233] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
OVERVIEW Increasing concerns over the potentially impairing effects of prescriptive sedative drugs such as benzodiazepines on driving have been raised. However, other alternatives such as natural medicines may also carry similar risks with respect to driving safety. Kava (Piper methysticum) is a psychotropic plant commonly used both recreationally and medicinally in the United States, Australia, and the South Pacific to elicit a physically tranquilizing effect. To date no controlled study has tested a medicinal dose of kava versus placebo and a standard sedative drug on driving ability and driving safety. OBJECTIVE Due to the need to establish the safety of kava in operating a motor vehicle, we compared the acute effects of the plant extract versus the benzodiazepine oxazepam and placebo using a driving simulator. METHODS A driving simulator (AusEd) was used by 22 adults aged between 18 and 65 years after being randomly administered an acute medicinal dose of kava (180 mg of kavalactones), oxazepam (30 mg), or placebo one week apart in a crossover design trial. RESULTS No impairing effects on driving outcomes were found after kava administration compared to placebo. Results on specific driving outcome domains revealed that the oxazepam condition had significantly slower braking reaction time compared to the placebo condition (p =.002) and the kava condition (p =.003). The kava condition had significantly fewer lapses of concentration compared to the oxazepam condition (p =.033). No significant differences were found between conditions for steering deviation, speed deviation, and number of crashes. Results were not modified by driving experience. On the Bond-Lader visual analogue sub-scale of alertness, a significant Treatment × Time interaction (p =.032) was found, with a significant reduction over time for oxazepam decreasing alertness (p <.001), whereas no significant reduction was found in the kava or placebo conditions. CONCLUSION The results indicate that a medicinal dose of kava containing 180 mg of kavalactones does not impair driving ability, whereas 30 mg of oxazepam shows some impairment. Research assessing larger recreational doses of kava on driving ability should now be conducted.
Collapse
Affiliation(s)
- J Sarris
- The University of Melbourne, Department of Psychiatry, Richmond, Melbourne, Victoria, Australia.
| | | | | | | | | | | | | |
Collapse
|
4
|
Zhang F, Drabier R. IPAD: the Integrated Pathway Analysis Database for Systematic Enrichment Analysis. BMC Bioinformatics 2012; 13 Suppl 15:S7. [PMID: 23046449 PMCID: PMC3439721 DOI: 10.1186/1471-2105-13-s15-s7] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Background Next-Generation Sequencing (NGS) technologies and Genome-Wide Association Studies (GWAS) generate millions of reads and hundreds of datasets, and there is an urgent need for a better way to accurately interpret and distill such large amounts of data. Extensive pathway and network analysis allow for the discovery of highly significant pathways from a set of disease vs. healthy samples in the NGS and GWAS. Knowledge of activation of these processes will lead to elucidation of the complex biological pathways affected by drug treatment, to patient stratification studies of new and existing drug treatments, and to understanding the underlying anti-cancer drug effects. There are approximately 141 biological human pathway resources as of Jan 2012 according to the Pathguide database. However, most currently available resources do not contain disease, drug or organ specificity information such as disease-pathway, drug-pathway, and organ-pathway associations. Systematically integrating pathway, disease, drug and organ specificity together becomes increasingly crucial for understanding the interrelationships between signaling, metabolic and regulatory pathway, drug action, disease susceptibility, and organ specificity from high-throughput omics data (genomics, transcriptomics, proteomics and metabolomics). Results We designed the Integrated Pathway Analysis Database for Systematic Enrichment Analysis (IPAD, http://bioinfo.hsc.unt.edu/ipad), defining inter-association between pathway, disease, drug and organ specificity, based on six criteria: 1) comprehensive pathway coverage; 2) gene/protein to pathway/disease/drug/organ association; 3) inter-association between pathway, disease, drug, and organ; 4) multiple and quantitative measurement of enrichment and inter-association; 5) assessment of enrichment and inter-association analysis with the context of the existing biological knowledge and a "gold standard" constructed from reputable and reliable sources; and 6) cross-linking of multiple available data sources. IPAD is a comprehensive database covering about 22,498 genes, 25,469 proteins, 1956 pathways, 6704 diseases, 5615 drugs, and 52 organs integrated from databases including the BioCarta, KEGG, NCI-Nature curated, Reactome, CTD, PharmGKB, DrugBank, PharmGKB, and HOMER. The database has a web-based user interface that allows users to perform enrichment analysis from genes/proteins/molecules and inter-association analysis from a pathway, disease, drug, and organ. Moreover, the quality of the database was validated with the context of the existing biological knowledge and a "gold standard" constructed from reputable and reliable sources. Two case studies were also presented to demonstrate: 1) self-validation of enrichment analysis and inter-association analysis on brain-specific markers, and 2) identification of previously undiscovered components by the enrichment analysis from a prostate cancer study. Conclusions IPAD is a new resource for analyzing, identifying, and validating pathway, disease, drug, organ specificity and their inter-associations. The statistical method we developed for enrichment and similarity measurement and the two criteria we described for setting the threshold parameters can be extended to other enrichment applications. Enriched pathways, diseases, drugs, organs and their inter-associations can be searched, displayed, and downloaded from our online user interface. The current IPAD database can help users address a wide range of biological pathway related, disease susceptibility related, drug target related and organ specificity related questions in human disease studies.
Collapse
Affiliation(s)
- Fan Zhang
- Department of Academic and Institutional Resources and Technology, University of North Texas Health Science Center, Fort Worth, USA
| | | |
Collapse
|
5
|
Sarris J, Scholey A, Schweitzer I, Bousman C, Laporte E, Ng C, Murray G, Stough C. The acute effects of kava and oxazepam on anxiety, mood, neurocognition; and genetic correlates: a randomized, placebo-controlled, double-blind study. Hum Psychopharmacol 2012; 27:262-9. [PMID: 22311378 DOI: 10.1002/hup.2216] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/26/2011] [Accepted: 01/11/2012] [Indexed: 02/03/2023]
Abstract
RATIONALE Kava (Piper methysticum) is a psychotropic plant medicine with history of cultural and medicinal use. We conducted a study comparing the acute neurocognitive, anxiolytic, and thymoleptic effects of a medicinal dose of kava to a benzodiazepine and explored for the first time specific genetic polymorphisms, which may affect the psychotropic activity of phytomedicines or benzodiazepines. METHODS Twenty-two moderately anxious adults aged between 18 and 65 years were randomized to receive an acute dose of kava (180 mg of kavalactones), oxazepam (30 mg), and placebo 1 week apart in a crossover design trial. RESULTS After exposure to cognitive tasks, a significant interaction was revealed between conditions on State-Trait Anxiety Inventory-State anxiety (p = 0.046, partial ŋ² = 0.14). In the oxazepam condition, there was a significant reduction in anxiety (p = 0.035), whereas there was no change in anxiety in the kava condition, and there was an increase in anxiety in the placebo condition. An increase in Bond-Lader "calmness" (p = 0.002) also occurred for the oxazepam condition. Kava was found to have no negative effect on cognition, whereas a reduction in alertness (p < 0.001) occurred in the oxazepam condition. Genetic analyses provide tentative evidence that noradrenaline (SLC6A2) transporter polymorphisms may have an effect on response to kava. CONCLUSION Acute "medicinal level" doses of this particular kava cultivar in naive users do not provide anxiolytic activity, although the phytomedicine also appears to have no negative effects on cognition.
Collapse
Affiliation(s)
- J Sarris
- The University of Melbourne, Department of Psychiatry, 2 Salisbury St., Richmond, Melbourne, Australia.
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Effects of oxazepam on affective perception, recognition, and event-related potentials. Psychopharmacology (Berl) 2011; 215:301-9. [PMID: 21197615 DOI: 10.1007/s00213-010-2141-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/17/2010] [Accepted: 12/05/2010] [Indexed: 10/18/2022]
Abstract
BACKGROUND Little is known about how rapid electrocortical responses (event-related potentials; ERPs) to affective pictures are modulated by benzodiazepine agonists. The present study investigated effects of oxazepam (20 mg p.o.) on behavioral measures and ERPs associated with affective picture processing during perception and recognition memory retrieval. METHODS Forty-three healthy young adults were given oxazepam or placebo treatment under a double-blind experimental procedure. Affective pictures (negatively arousing or neutral) elicited ERP responses and participants rated pictures for emotionality (during incidental encoding) and recognition. RESULTS Oxazepam did not affect perceptual (P1, P2) or emotional (early posterior negativity and late parietal positivity) ERPs or ratings during perception. However, oxazepam impaired recognition performance and decreased positive mid-frontal ERP component at 420-450 ms for old vs. new pictures. The memory impairment was retained at the delayed memory test. CONCLUSIONS Oxazepam does not selectively influence electrocortical or perceptual indexes of emotional perception or emotional memory. Rather, it blocks memory consolidation independent of valence category. These findings indicate that ERPs can be of use in assessing effects of benzodiazepines on memory-related processes.
Collapse
|
7
|
LaPorte E, Sarris J, Stough C, Scholey A. Neurocognitive effects of kava (Piper methysticum): a systematic review. Hum Psychopharmacol 2011; 26:102-11. [PMID: 21437989 DOI: 10.1002/hup.1180] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/15/2010] [Accepted: 01/21/2011] [Indexed: 11/10/2022]
Abstract
RATIONALE Kava (Piper methysticum) elicits dose-dependent psychotropic effects and thus may potentially deleteriously affect cognitive performance. Clinical trials have assessed the effects of kava on cognition, however, to our knowledge no systematic review has been conducted in this area. OBJECTIVE To systematically review the effects of kava on cognition, providing an analysis of the individual study's methodological quality, results and effect sizes. METHODS A systematic review was conducted of publications up to June 15th 2010, using the electronic databases MEDLINE, PsychINFO, CINAHL, Web of Science and The Cochrane Library. The search criteria involved kava and cognition related terms, e.g. memory and attention. RESULTS Ten human clinical trials met inclusion criteria (acute n = 7, chronic n = 3). One acute study found that kava significantly improved visual attention and working memory processes while another found that kava increased body sway. One chronic study found that kava significantly impaired visual attention during high-cognitive demand. Potential enhanced cognition may be attributed to the ability of kava to inhibit re-uptake of noradrenaline in the pre-frontal cortex, while increased body sway may be due to GABA pathway modulation. CONCLUSIONS The majority of evidence suggests that kava has no replicated significant negative effects on cognition.
Collapse
Affiliation(s)
- E LaPorte
- Brain Sciences Institute, University of Technology, Melbourne, Victoria, Australia.
| | | | | | | |
Collapse
|
8
|
Kenemans JL, Kähkönen S. How human electrophysiology informs psychopharmacology: from bottom-up driven processing to top-down control. Neuropsychopharmacology 2011; 36:26-51. [PMID: 20927044 PMCID: PMC3055493 DOI: 10.1038/npp.2010.157] [Citation(s) in RCA: 89] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/01/2010] [Revised: 08/10/2010] [Accepted: 08/11/2010] [Indexed: 01/28/2023]
Abstract
This review surveys human event-related brain potential (ERP) and event-related magnetic field (ERF) approaches to psychopharmacology and psychopathology, and the way in which they complement behavioral studies and other neuroimaging modalities. The major paradigms involving ERP/ERF are P50 suppression, loudness-dependent auditory evoked potential (LDAEP), mismatch negativity (MMN), P300, mental chronometry, inhibitory control, and conflict processing (eg, error-related negativity (ERN)). Together these paradigms cover a range of more bottom-up driven to more top-down controlled processes. A number of relationships between the major neurotransmitter systems and electrocortical mechanisms are highlighted. These include the role of dopamine in conflict processing, and perceptual processing vs motor preparation; the role of serotonin in P50 suppression, LDAEP, and MMN; glutamate/NMDA and MMN; and the role of acetylcholine in P300 generation and memory-related processes. A preliminary taxonomy for these relationships is provided, which should be helpful in attuning possible new treatments or new applications of existing treatments to various disorders.
Collapse
Affiliation(s)
- J Leon Kenemans
- Department of Experimental Psychology and Human Psychopharmacology, Utrecht University, Utrecht, The Netherlands.
| | | |
Collapse
|
9
|
Puga F, Sampaio I, Veiga H, Ferreira C, Cagy M, Piedade R, Ribeiro P. The effects of bromazepam on the early stage of visual information processing (P100). ARQUIVOS DE NEURO-PSIQUIATRIA 2007; 65:955-9. [DOI: 10.1590/s0004-282x2007000600006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/24/2006] [Accepted: 08/11/2007] [Indexed: 11/22/2022]
Abstract
The early stages of visual information processing, involving the detection and perception of simple visual stimuli, have been demonstrated to be sensitive to psychotropic agents. The present study investigated the effects of an acute dose of bromazepam (3 mg), compared with placebo, on the P100 component of the visual evoked potential and reaction time. The sample, consisting of 14 healthy subjects (6 male and 8 female), was submitted to a visual discrimination task, which employed the "oddball" paradigm. Results suggest that bromazepam (3 mg) impairs the initial stage of visual information processing, as observed by an increase in P100 latency.
Collapse
|
10
|
Cristini P, Fournier C, Timsit-Berthier M, Bailly M, Tijus C. [ERPs (N200, P300 and CNV) in alcoholics: relapse risk assessment]. Neurophysiol Clin 2003; 33:103-19. [PMID: 12909389 DOI: 10.1016/s0987-7053(03)00027-3] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
The cognitive event-related potentials were studied in a group of 55 alcoholic patients, paired in age and sex with a group of 18 control subjects, using a protocol oddball (visual and auditory) and a protocol VCN Go/Nogo. The N200 obtained using an auditory oddball paradigm had lower amplitude in alcoholics than in controls. A significant amplitude decrease of visual P300 was also observed in alcoholic male subjects. There was however no difference in auditory P300 between alcoholics and control subjects. Using a Go/Nogo paradigm, a significant difference on the final part of the VCN appears between alcoholic and pilot subjects. In addition, the longitudinal follow-up of the same alcoholic patients showed an electrophysiological profile that allowed dividing them into two different groups. On the initial recording (17 days after weaning), the auditory oddball P300 amplitude was significantly higher at Cz and Pz among patients who relapsed during the 3 months follow-up. The same effect appeared on the CNV protocol, where the amplitude of P300 was higher in patients who subsequently relapsed than for those who remained abstinent. Cognitive ERPs may be clinically useful to improve the prediction of risk of relapse among alcoholic patients.
Collapse
Affiliation(s)
- P Cristini
- Traitement et recherche sur l'alcoolisme, centre hospitalier de Decize, unité associée CNRS FRE 7021, 74, route de Moulins, BP 65, 58301 Decize cedex, France.
| | | | | | | | | |
Collapse
|
11
|
Lucchesi LM, Pompéia S, Manzano GM, Kohn AF, Galduroz JCF, Bueno OFA, Tufik S. Flunitrazepam-induced changes in neurophysiological, behavioural, and subjective measures used to assess sedation. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:525-33. [PMID: 12691789 DOI: 10.1016/s0278-5846(03)00044-7] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
INTRODUCTION Certain features of event-related potentials (ERPs), electroencephalographic (EEG), and behavioural measures vary with differing states of alertness and/or sedation. PURPOSE This study was conducted to investigate changes in several measures usually viewed as reflecting states of sedation/sleepiness associated with the use of a range of doses of the hypnotic benzodiazepine (BZD) flunitrazepam (FNZ). METHODS This was a double blind, independent group design study of the effects of acute oral doses of FNZ in young healthy volunteers. Forty-eight subjects were randomly allocated to one of four groups-FNZ (0.6, 0.8, and 1.0 mg) and placebo (PLAC)-and tested prior to treatment and then in a posttreatment session close to the theoretical peak plasma concentration. ERP latencies and amplitudes were measured at midfrontal (Fz), midcentral (Cz), and midparietal (Pz) using a standard auditory oddball paradigm. EEG changes were assessed at Pz. Behavioural measures included the digit-symbol substitution test (DSST), a cancellation task (CT), and subjective ratings of alertness and attentiveness by the subjects (SUB) and the experimenter (EXP). RESULTS FNZ led to psychomotor impairments and decreased alertness and attention; these effects were consistent with previous findings. A progressive, dose-related increase in P3 latency occurred in Fz, Cz, and Pz, and there was an increase in N1 (Fz, Cz) and N2 (Fz). N2-P3 amplitude decreased in Fz. EEG power bands beta 1 increased for the two highest doses, but no significant differences were noted in theta, delta, and alpha bands. P3 latencies, experimenter-rated levels of alertness, and DSST scores differentiated all three doses of FNZ from PLAC. CONCLUSION The most sensitive measures used were P3 latencies of the ERPs (which varied with FNZ dose), DSST, and the experimenter-rated levels of alertness. However, we found no evidence for the assumption that one single phenomenon was reflected in all measures and different mechanisms were probably involved. Further experiments will be needed for more in-depth probing of the finer mechanisms underlying sedation/sleepiness and how they affect behavioural and eletrophysiological measures of the central nervous system (CNS) function.
Collapse
Affiliation(s)
- Lígia M Lucchesi
- Department of Psychobiology, Universidade Federal de São Paulo, R. Napoleão de Barros, 925 V. Clementino, CEP: 04024-002, São Paulo, SP, Brazil.
| | | | | | | | | | | | | |
Collapse
|
12
|
Abstract
Sensory or P50 gating, as measured with the double click paradigm, reflects a slow inhibitory preattentional information process. It protects living organisms from being flooded by environmental stimuli. The effects of a single dose of diazepam (10 mg) on the amplitude of the P50's and P50 gating, as measured from auditory evoked potentials elicited by double clicks (80 dB white noise, interstimulus interval 500 ms) were investigated in a double blind, placebo controlled study in healthy volunteers. P50 gating was found, however diazepam had no effects on the amplitude of the P50, nor on P50 gating. The results contribute to the specificity of psychoactive drugs to control gating and demonstrate that this slow inhibitory process is not effected by this benzodiazepine. Moreover, the results confirm that P50 and P50 gating are indeed preattentive processes that are not controlled by diazepam.
Collapse
Affiliation(s)
- Gilles van Luijtelaar
- NICI-Biological Psychology, University of Nijmegen, PO Box 9104, 6500 HE Nijmegen, the Netherlands.
| |
Collapse
|
13
|
Murakami T, Nakagome K, Kamio S, Kasai K, Iwanami A, Hiramatsu KI, Fukuda M, Hata A, Honda M, Watanabe A, Kato N. The effects of benzodiazepines on event-related potential indices of automatic and controlled processing in schizophrenia: a preliminary report. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26:651-61. [PMID: 12188096 DOI: 10.1016/s0278-5846(01)00302-5] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
The effects of benzodiazepines on cognitive function in schizophrenic patients were investigated using event-related potential (ERP) measurement during an auditory selective attention task. In this study, the authors compared the mismatch negativity (MMN) and N2b components between two subgroups of schizophrenic patients: one is comprised of patients who received no benzodiazepines (NT group, n = 7) and the other is comprised of those administered benzodiazepines in the daytime (T group, n = 7). There were no significant differences in MMN and N2b amplitudes between the two subgroups, whereas the N2b latency was significantly prolonged in the T group relative to the NT group. This suggested that benzodiazepines induce delayed stimulus classification processing in schizophrenic patients.
Collapse
Affiliation(s)
- Tadashi Murakami
- Department of Neuropsychiatry, Faculty of Medicine, University of the Ryukyus, Okinawa, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Hansenne M. [The p300 cognitive event-related potential. I. Theoretical and psychobiologic perspectives]. Neurophysiol Clin 2000; 30:191-210. [PMID: 11013894 DOI: 10.1016/s0987-7053(00)00223-9] [Citation(s) in RCA: 64] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Abstract
The P300 is a positive wave which arises when an attended stimulus is detected. Its parameters depend on a number of variables, in particular the subject's mental state, the task that has to be accomplished, the significance of the stimulus, and the degree of attention. It can be recorded with accuracy, and the different stages of information processing can therefore be analyzed. The P300 wave shows the modifications in neuronal activity which take place during the cognitive process: P300 latency provides an indirect indication of the duration of the processes involved in stimulus discrimination while its amplitude, which is influenced by a number of variables, provides an index of the intensity of the energetic activation or arousal involved. The P300 wave consists of several components which reflect distinct information-processing events (P3a, P3b, P3e, P-SR, P-CR). According to the theoretical models, it is hypothesized that P300 could either represent the adaptation of the working memory to further environmental input ('context updating'), or indicate a closing process ('context closure') in information processing. As regards the physiological aspect of P300 and its association with cortical networks, various studies have suggested that several cortical generators of P300 may co-exist: the medial temporal lobe, the temporo-parietal junction, and the medial and lateral frontal lobe. Psychopharmacological studies have shown that different neurotransmitter systems are involved in the generation and modulation of P300, namely the cholinergic, noradrenergic, dopaminergic, serotoninergic and gabaergic systems. It appears that the noradrenergic agonists increase the amplitude of P300, dopaminergic agonists may have a biphasic effect (increase/reduction), while cholinergic antagonists and gabaergic agonists reduce P300 amplitude and prolong its latency.
Collapse
Affiliation(s)
- M Hansenne
- Université de Liège, service de psychiatrie et de psychologie médicale, CHU du Sart-Tilman (B35), Belgique
| |
Collapse
|